PepGen Inc (PEPG)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.32-5.31%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · PEPG
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-11-05 · Compared with 117 industry peers
PEPG — officer change
Dated 2025-11-07
The filing describes a repricing of underwater stock options for current employees, including executive officers.
Why it matters: This readout tests safety and signs of benefit after repeat dosing. PepGen said results were due in November.
Watch forNovember data show repeat dosing is tolerable. Splicing or vHOT measures are better than in the 5 mg/kg cohort.
Also watch forData show serious safety concerns, no gains in splicing or vHOT measures, or a delayed readout.
Why it matters: PepGen has no approved product listed in these inputs. Its trial work depends on cash to continue.
Worry ifCash falls below the level needed to fund work into 4Q 2027, or PepGen shortens its runway estimate.
Less concerning ifPepGen keeps its stated runway into 4Q 2027 and reports cash above the level needed for planned trials.
Why it matters: The update can show whether people stay in the study as dosing rises from 5 to 10 mg/kg.
Watch forPepGen reports the update by early January, with no new safety issue. Participation at 10 mg/kg continues.
Also watch forThe update is delayed, participants leave due to safety concerns, or dosing at 10 mg/kg is stopped.
Why it matters: This is the trial's highest planned dose. Its results may shape PepGen's next trial plan.
Watch forPepGen enrolls the 12.5 mg/kg group and reports results in 1H 2027, with no new safety issue disclosed.
Also watch forEnrollment or results slip past 1H 2027, or the company reports a safety issue that stops dose testing.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$324 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $869 loss on $10,000 · 8.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,117 loss on $10,000 · 81.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.